4//SEC Filing
DAVIE JOSEPH MD PHD 4
Accession 0001181431-09-020147
CIK 0000921506other
Filed
Apr 15, 8:00 PM ET
Accepted
Apr 16, 4:57 PM ET
Size
6.1 KB
Accession
0001181431-09-020147
Insider Transaction Report
Form 4
DAVIE JOSEPH MD PHD
Director
Transactions
- Exercise/Conversion
Nonqualified Stock Option (right to buy)
2009-04-14$11.26/sh−2,500$28,150→ 0 totalExercise: $8.74From: 2008-06-20Exp: 2018-05-20→ Common Stock (2,500 underlying)
Footnotes (1)
- [F1]This option to purchase shares of the Issuer's stock, which provided that 8.33% of the shares subject to the option shall vest per month over the 12 month period following the May 20, 2008 date of grant, became 100% vested and exercisable due to a change in control of the Issuer effected through the tender offer by Apex Merger Sub, Inc. ("Apex"), a wholly owned subsidiary of Gilead Sciences, Inc. ("Gilead), effective as of April 14, 2009. The Issuer will make a cash payment of $21,150, representing the gross cash amount for the remaining shares subject to this option which became 100% vested and exercisable due to the change in control, to the Reporting Party.
Issuer
CV THERAPEUTICS INC
CIK 0000921506
Entity typeother
Related Parties
1- filerCIK 0001216660
Filing Metadata
- Form type
- 4
- Filed
- Apr 15, 8:00 PM ET
- Accepted
- Apr 16, 4:57 PM ET
- Size
- 6.1 KB